KBR 7785

Drug Profile

KBR 7785

Latest Information Update: 26 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Organon
  • Class Antihyperglycaemics; Antirheumatics; Hydroxamic acids; Small molecules
  • Mechanism of Action Matrix metalloproteinase 1 inhibitors; Matrix metalloproteinase 3 inhibitors; Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Graft-versus-host disease; Type 2 diabetes mellitus

Most Recent Events

  • 19 May 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Japan (Parenteral)
  • 12 Mar 2002 A study has been added to the Diabetes pharmacodynamics section
  • 01 Jun 2000 Preclinical development for Graft-versus-host disease in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top